Healthcare News

Infex Therapeutics to present new RESP-X Phase IIa data in late-breaking session at ERS Congress 2026 Presentation will provide additional analysis from the Phase IIa study of RESP-X in Pseudomonas...

VANCOUVER, British Columbia, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through...

Infex Therapeutics to present new RESP-X Phase IIa data in late-breaking session at ERS Congress 2026 Presentation will provide additional analysis from the Phase IIa study of RESP-X in Pseudomonas...

Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio® (inclisiran) vs. bempedoic acid in achieving LDL-C goalsNew AZALEA-TIMI 71 analyses will further characterize the bleeding profile...

NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived...

Immunocine Cancer Center Expands as Demand Grows for Personalized Dendritic Cell Therapy. New location Opens in Cabo San Lucas Mexico.

Strategic Partnership Positions Flyte as the Premier Regional Aviation Solution for Statewide Campaigns While Expanding Access to More Than 5,000 Candidates, SuperPACs and Political Organizations ...

WALTHAM, Mass., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in...

Follows recent European patent grant and coverage in multiple international markets as Silo continues to strengthen licensed IP portfolio for lead therapeutic program SARASOTA, FLA., Aug. 18, 2026 ...

Chairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event on Thursday, August 20, 2026